Product Description
A small-molecule proapoptotic agent with potential antineoplastic activity. Sepantronium bromide selectively inhibits survivin expression in tumor cells, resulting in inhibition of survivin antiapoptotic activity (via the extrinsic or intrinsic apoptotic pathways) and tumor cell apoptosis. Survivin, a member of the inhibitor of apoptosis (IAP) gene family, is expressed during embryonal development and is absent in most normal, terminally differentiated tissues; upregulated in a variety of human cancers, its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sepantronium-bromide)
Mechanisms of Action: Survivin mRNA Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Lymphoma, Non-Hodgkin|Burkitt Lymphoma|Non-Small-Cell Lung Cancer|Diffuse Large B-Cell Lymphoma|Breast Cancer|Prostate Cancer|Adenocarcinoma|Small Cell Lung Cancer|Melanoma|Lymphoma, B-Cell|Follicular Lymphoma
Phase 1: Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HGBCL | P2 |
Unknown status |
Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Burkitt Lymphoma |
2023-09-01 |
57% |
| 2009-012439-14 | P2 |
Completed |
Breast Cancer|Adenocarcinoma |
2013-06-27 |
|
| 155-CL-031 | P2 |
Completed |
Lymphoma, Non-Hodgkin |
2013-03-01 |
|
| 10-C-0051 | P2 |
Completed |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2012-12-01 |